Consistent with the observation that NHE1 inhibition can reduce ventricular arrhythmias [20, 21], the present study found that NHE1 inhibition with sabiporide dose-dependently reduced ventricular premature beats and ventricular tachycardia and prevented ventricular fibrillation and early death. This evidence concerns the gene SLC9A1 and ventricular tachycardia.